rPFS End Point Met with 177Lu-PSMA in Phase 3 Trial for mCRPC
Durable Antitumor Activity in ccRCC With Combination Belzutifan/Cabozantinib
“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.
Darolutamide Correlates With Longer Time on Treatment Discontinuation in nmCRPC
Real-world data hint that darolutamide may lengthen time to treatment discontinuation and more, in patients with non-metastatic castration-resistant prostate cancer.
Antitumor Activity Associated With Pembrolizumab in BCG-Unresponsive Papillary NMIBC
Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.
Darolutamide Maintains Safety in Nonmetastatic CRPC, According to Long-Term Data
At the final analysis of the ARAMIS study, darolutamide reduced the risk of death by 31% compared with placebo in patients with nonmetastatic castration-resistant prostate cancer.
The Latest Treatment Advances in Prostate Cancer
In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.
Enfortumab Plus Pembrolizumab Displays High ORR in Metastatic Urothelial Cancer
The combination of enfortumab vedotin plus pembrolizumab led to a confirmed overall response rate of 64.5% in patients with metastatic urothelial cancer.
Improved Recurrence-Free Survival is not Seen with Perioperative Nivolumab in RCC
Perioperative nivolumab in patients with RCC, at high risk for recurrence, did not see an improved RFS, but analyses within the phase 3 trial could inform future research.
Reduced Risk of Metastatic Progression With Darolutamide in Patients With nmCRPC
Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
Maintenance Cabozantinib Fails to Show Significant Benefit in Advanced Urothelial Carcinoma
Updates Results of Adjuvant Pembrolizumab in RCC Shows Sustained DFS Benefit
Updated findings from the phase 3 KEYNOTE-564 trial may further support adjuvant pembrolizumab as a new standard of care for patients with renal cell carcinoma with high risk of recurrence.
Darolutamide Remains Safe/Effective in Patients With nmCRPC and Comorbidities Receiving Concomitant Medications
In a subgroup analysis of the ARAMIS study, the safety and efficacy of darolutamide were not impacted by patients having comorbidities and receiving concomitant medications.
Darolutamide Significantly Stalls Time to Deterioration of HRQOL in Patients With nmCRPC
Darolutamide has shown an impact on local symptoms in patients with nonmetastatic castration-resistant prostate cancer. One of the impacts was a delay in time to HRQOL deterioration.
Abiraterone Added to ADT and Docetaxel Prolongs PFS in De Novo mCSPC
In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.
Early Genomic Profiling Performed Less in African American Men With Prostate Cancer
Disparities in prostate cancer care have been highlighted through a study examining genomic profiling.
Trimodal Pembrolizumab-Based Regimen, which is Bladder-Sparing Shows Promise in MIBC
The protocol of pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy for muscle-invasive bladder cancer demonstrated safety and efficacy.
Investigational PSMA-Targeted Treatment Demonstrates Antitumor Activity in mCRPC
In patients with metastatic castration-resistant prostate cancer treated in a phase 1/2a study, the HPN424, a tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager was well tolerated and demonstrated antitumor activity.
Early Study Explores Novel Combinations in Advanced RCC
In patients with advanced clear cell renal cell carcinoma, a phase 1b/2 umbrella platform study is evaluating the safety and efficacy of experimental combinations of investigational agents.
Long-Term Responders of Apalutamide Identified With Molecular Signature in nmCRPC
A molecular signature has been identified that can characterize long-term responders from treatment with apalutamide and androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, according to findings, presented at the 2021 Genitourinary Cancers Symposium.
Apalutamide With ADT Maintains OS Benefit in mCSPC
Apalutamide in combination with androgen deprivation therapy led to a reduction in the risk of death of 35% in comparison with ADT alone for patients with metastatic castration-sensitive prostate cancer in a final analysis of the phase 3 TITAN trial.
In ARAMIS Trial, Crossover Has Minimal Impact on Darolutamide OS Benefit
In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.
Durvalumab With or Without Tremelimumab Fails to Meet OS Endpoints in Urothelial Cancer
The co-primary end points of overall survival in patients with metastatic urothelial cancer were not met in the phase 3 DANUBE trial of durvalumab in combination with tremelimumab and durvalumab monotherapy, according to results presented at the 2020 ESMO Virtual Congress.
Durable Benefit Observed at 4 Years With Nivolumab Plus Ipilimumab in Advanced RCC
At 4 years of follow-up, nivolumab and ipilimumab in combination as first-line therapy of advanced renal cell carcinoma demonstrated durable benefit versus sunitinib, according to research presented at the 2020 ESMO Virtual Congress.
2 Clarke Drive Cranbury, NJ 08512